Trial Profile
Risk of adverse pregnancy outcomes with Leflunomide exposure during early pregnancy in Quebec Pregnancy Cohort.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Dec 2017
Price :
$35
*
At a glance
- Drugs Leflunomide (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Sanofi
- 08 Dec 2017 Results assessing the risk of major congenital malformation, prematurity, low birth weight and spontaneous abortion associated with leflunomide exposure during pregnancy published in the Annals of the Rheumatic Diseases
- 25 Sep 2017 New trial record
- 30 Aug 2017 Results presented at the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management